| scholarly article | Q13442814 |
| P50 | author | Neil E Kay | Q54295335 |
| Donna Neuberg | Q87319577 | ||
| Nyla A Heerema | Q89317565 | ||
| P2093 | author name string | Paola Dal Cin | |
| Thomas J Kipps | |||
| Lillian Werner | |||
| Daniel L Van Dyke | |||
| Laura Z Rassenti | |||
| Andrew W Greaves | |||
| Marie Dell Aquila | |||
| Chandrika Sreekantaiah | |||
| Emanuella Ghia | |||
| P2860 | cites work | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. | Q27853022 |
| Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia | Q28087672 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
| A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia | Q33515409 | ||
| Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia | Q33595764 | ||
| Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia | Q34016413 | ||
| Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia | Q34974058 | ||
| miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia | Q35220412 | ||
| High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome | Q35906329 | ||
| Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression | Q36286867 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia | Q36843749 | ||
| Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia | Q36906625 | ||
| De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience | Q37028638 | ||
| Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium | Q37149182 | ||
| 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia | Q38491230 | ||
| Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort | Q40880741 | ||
| Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. | Q41875368 | ||
| Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. | Q45988365 | ||
| Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. | Q53596463 | ||
| Non-coding recurrent mutations in chronic lymphocytic leukaemia | Q56996904 | ||
| High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations | Q57272648 | ||
| Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia | Q73267761 | ||
| Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia | Q83511917 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 105-113 | |
| P577 | publication date | 2016-02-05 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience | |
| P478 | volume | 173 |
| Q90262439 | "Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia |
| Q50524485 | Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. |
| Q56270980 | Chronic lymphocytic leukaemia |
| Q33648906 | Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients |
| Q47133291 | Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion |
| Q37429218 | Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. |
| Q50330301 | FISH Panel for Leukemic CTCL. |
| Q90071548 | Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Q90690187 | IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes |
| Q49864609 | Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia |
| Q98288773 | Increased Expression of Autophagy Protein LC3 in Two Patients With Progressing Chronic Lymphocytic Leukemia |
| Q48138435 | Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. |
| Q37697093 | Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations |
| Q46103134 | MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia |
| Q44752987 | Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. |
| Q93115037 | Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report |
| Q48181248 | The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab |
| Q57802917 | The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia without treatment indication |
Search more.